Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals (NASDAQ:IONS) stands at 58,508 shares.

Scientists have unveiled insights into how HIV-1, the virus responsible for AIDS, skillfully hijacks cellular machinery for its own survival. By dissecting the molecular interplay between the virus ...

Sunburn has traditionally been attributed to UV-induced DNA damage. However, a new study by the University of Copenhagen and Nanyang Technological University, Singapore, reveals that RNA, another ...

Our genes contain all the instructions our body needs to function, but their expression must be finely regulated to guarantee ...

Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

Mice injected with a microRNA molecule lived longer and had fewer markers of ageing, but it’s not yet known if the treatment ...

Three students from Centreville High School in Clifton discovered a potentially harmful substance – DNA residues, or tiny ...

Researchers led by François Fuks - Laboratory of Cancer Epigenetics, ULB Faculty of Medicine, ULB-Cancer Research Center and ...

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

New genetic research shows why some people develop deadly Huntington's disease earlier than others. The findings could lead ...